PARPi Response Evaluation for Clinical Impact and Scientific Innovation in Oncology: The PRECISION Registry

PARP inhibitors (PARPis) have heralded the era of “precision medicine” for prostate cancer (PCA) and are the first class of therapeutic agents designed to exploit synthetic lethality.

There is now a critical need to develop an international, collaborative registry of patients with clinical and genomic data from men with DNA repair mutations who have been treated with PARPis to collectively assess responses and modifiers of response to catapult novel directions for therapeutic development and clinical trials in men with PCA.

The PRECISION Registry is the first registry to include data from PARPi trials, clinical use, PCA registries, and the Veterans Affairs (VA) population to comprehensively assess PARPi responses and explore novel biomarkers of response to optimize patient selection for PARPis and yield critical research directions to enhance the impact of these agents.